A Argiris

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy
    Athanassios Argiris
    Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 22:262-8. 2004
  2. ncbi Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Cancer 101:2222-9. 2004
  3. ncbi Revisiting induction chemotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Chicago, Illinois 60611, USA
    Oncology (Williston Park) 19:759-70. 2005
  4. ncbi A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer
    A Argiris
    Division of Hematology Oncology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Lung Cancer 45:243-53. 2004
  5. ncbi Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Athanassios Argiris
    Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Lung Cancer 43:317-22. 2004
  6. ncbi Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Head Neck 26:447-55. 2004
  7. ncbi Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Cancer Res 10:1956-62. 2004
  8. ncbi Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
    A Argiris
    Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Ann Oncol 14:1306-11. 2003
  9. ncbi Esthesioneuroblastoma: the Northwestern University experience
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Laryngoscope 113:155-60. 2003
  10. ncbi Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
    J K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Ann Oncol 19:1787-94. 2008

Detail Information

Publications53

  1. ncbi Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy
    Athanassios Argiris
    Feinberg School of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    J Clin Oncol 22:262-8. 2004
    ..To evaluate the outcome of elderly patients with head and neck cancer undergoing palliative chemotherapy...
  2. ncbi Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Cancer 101:2222-9. 2004
    ....
  3. ncbi Revisiting induction chemotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Chicago, Illinois 60611, USA
    Oncology (Williston Park) 19:759-70. 2005
    ..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents...
  4. ncbi A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer
    A Argiris
    Division of Hematology Oncology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Lung Cancer 45:243-53. 2004
    ....
  5. ncbi Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Athanassios Argiris
    Division of Hematology Oncology, The Feinberg School of Medicine, Northwestern University, 676 N St Clair, Suite 850, Chicago, IL 60611, USA
    Lung Cancer 43:317-22. 2004
    ..To evaluate the efficacy of single-agent gefitinib (Iressa, ZD1839), an oral, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, as first-line compassionate use therapy for advanced non-small-cell Lung cancer (NSCLC)...
  6. ncbi Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Head Neck 26:447-55. 2004
    ..The purpose of this study was to evaluate the role of neck lymph node (ND) in the combined dissection modality therapy for locoregionally advanced head and neck...
  7. ncbi Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy
    Athanassios Argiris
    The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Clin Cancer Res 10:1956-62. 2004
    ....
  8. ncbi Concurrent chemoradiotherapy for N2 or N3 squamous cell carcinoma of the head and neck from an occult primary
    A Argiris
    Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Ann Oncol 14:1306-11. 2003
    ..Our aim was to explore the use of concurrent chemoradiotherapy in the management of patients with squamous cell carcinoma of the head and neck from an occult primary (HNCOP)...
  9. ncbi Esthesioneuroblastoma: the Northwestern University experience
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Medical School, Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Laryngoscope 113:155-60. 2003
    ..To review our experience with esthesioneuroblastoma, a rare malignancy of the head and neck...
  10. ncbi Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels
    J K Salama
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Ann Oncol 19:1787-94. 2008
    ..Additionally, we systematically lowered radiotherapy (RT) doses attempting to maintain LRC while decreasing toxicity...
  11. ncbi Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer
    A Argiris
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, 5150 Centre Avenue, Pittsburgh, PA 15232, USA
    Ann Oncol 22:2482-8. 2011
    ..We studied the combination of pemetrexed, a multi-targeted antifolate, and cetuximab, an mAb against the epidermal growth factor receptor, with radiotherapy in poor prognosis head and neck cancer...
  12. ncbi Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy
    V A Passero
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh and Head and Neck Cancer Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, SA
    Ann Oncol 21:2278-83. 2010
    ..F]fluorodeoxyglucose-positron emission tomography (PET) scan may be useful in assessing treatment response and predicting patient outcome...
  13. ncbi Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer
    S S Agarwala
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, PA 15232, USA
    Ann Oncol 18:1224-9. 2007
    ..Our goal was to evaluate long-term efficacy outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) treated with carboplatin, paclitaxel (Taxol) and radiotherapy...
  14. ncbi Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents
    A Argiris
    Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    Cancer J 7:228-35. 2001
    ..These data support further evaluation of the newer chemotherapeutic drugs, and especially the camptothecins (irinotecan and topotecan) and the taxanes (paclitaxel and docetaxel), in the initial treatment of SCLC...
  15. ncbi Staging and clinical prognostic factors for small-cell lung cancer
    A Argiris
    Northwestern University Medical School and Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer J 7:437-47. 2001
    ..Identification of risk factors for treatment-related mortality is important for the management of patients with SCLC...
  16. ncbi Phase II trial of 9-aminocamptothecin as a 72-h infusion in cutaneous T-cell lymphoma
    A Argiris
    Northwestern University Medical School, Division of Hematology-Oncology, and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Invest New Drugs 19:321-6. 2001
    ....
  17. ncbi Empowering induction therapy for locally advanced head and neck cancer
    A Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Ann Oncol 22:773-81. 2011
    ....
  18. ncbi Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    A Argiris
    Department of Medicine, Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, San Antonio, USA
    Ann Oncol 24:220-5. 2013
    ..Conclusions Cetuximab and bevacizumab are supported by preclinical observations and are well tolerated and active in previously treated patients with SCCHN...
  19. ncbi Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas
    Michalis V Karamouzis
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    JAMA 298:70-82. 2007
    ..Given the biological importance of epidermal growth factor receptor (EGFR) in cancer development and progression, EGFR inhibitors have emerged as promising novel therapies...
  20. ncbi Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    J Thorac Oncol 1:52-60. 2006
    ..The study of molecular markers may identify the subset of patients who are the most appropriate to treat with these agents...
  21. ncbi Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck
    Jill Gilbert
    Division of Hematology and Oncology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Clin Adv Hematol Oncol 4:611-9. 2006
    ..The addition of novel, targeted agents to traditional therapies holds promise for clinical benefit. This review will focus on new agents that are promising and their potential role in the treatment of SCCHN...
  22. ncbi Targeting growth factors and angiogenesis; using small molecules in malignancy
    Harold J Wanebo
    Department of Surgery, Division Surgical Oncology, Roger Williams Medical Center, Providence, RI, USA
    Cancer Metastasis Rev 25:279-92. 2006
    ....
  23. ncbi A phase II trial of doxorubicin and interferon alpha 2b in advanced, non-medullary thyroid cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, UPMC Cancer Pavilion, 5th Floor, Pittsburgh, PA 15232, USA
    Invest New Drugs 26:183-8. 2008
    ..The combination of doxorubicin and interferon alpha is supported by preclinical data. We sought to evaluate the efficacy of this combination in patients with advanced thyroid cancer...
  24. ncbi Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT
    Jayakar V Nayak
    Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Laryngoscope 117:2129-34. 2007
    ..To determine whether combined positron emission tomography and computed tomography (PET-CT) may be of value in deferring planned neck dissections for patients with advanced head and neck squamous cell carcinoma (HNSCC)...
  25. ncbi A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores
    Susan Yount
    Center on Outcomes, Research and Education CORE, Evanston Northwestern Healthcare, Evanston, IL 60201, USA
    Qual Life Res 16:1615-26. 2007
    ..To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI)...
  26. ncbi Long-term results of a phase III randomized trial of postoperative radiotherapy with or without carboplatin in patients with high-risk head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Laryngoscope 118:444-9. 2008
    ..The role of postoperative radiotherapy and carboplatin in squamous cell carcinoma of the head and neck (SCCHN) has not been established...
  27. ncbi The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Mary J Fidler
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 14:2088-94. 2008
    ..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC...
  28. ncbi Head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15232, USA
    Lancet 371:1695-709. 2008
    ..We review the epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck...
  29. ncbi Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at
    Narissa J Nonzee
    Robert H Lurie Comprehensive Cancer Center and Division of Hematology Oncology, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 113:1446-52. 2008
    ..Few studies have examined the costs of supportive care for radiochemotherapy-induced mucosits/pharyngitis among patients with head and neck cancer (HNC) or lung cancers despite the documented negative clinical impact of these complications...
  30. ncbi A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    Cancer Biol Ther 5:766-70. 2006
    ..Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts...
  31. ncbi Planned post-chemoradiation neck dissection: significance of radiation dose
    Kerstin M Stenson
    Department of Surgery, Section of Otolaryngology Head and Neck Surgery, University of Chicago, Illinois 60637, USA
    Laryngoscope 116:33-6. 2006
    ..We report the pathologic data on patients undergoing neck dissection (ND) after induction chemotherapy followed by concomitant chemoradiotherapy (IC-CRT) in three similar protocols utilizing decreasing doses of radiation therapy...
  32. ncbi Update on chemoradiotherapy for head and neck cancer
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University Medical School and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Curr Opin Oncol 14:323-9. 2002
    ..Many issues remain to be addressed in future trials, including the optimal chemotherapy regimen, the use of altered fractionation radiotherapy, and the role of induction chemotherapy...
  33. ncbi Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer
    Eric Bleickardt
    Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Cancer Biol Ther 1:646-51. 2002
    ..Phase II trials of this regimen are ongoing or planned in lung, head and neck, stomach, esophageal, and pancreatic cancers...
  34. ncbi Progress in the therapy of small cell lung cancer
    Miklos Simon
    Section of Medical Oncology, Yale University School of Medicine, P.O. Box 208032, 333 Cedar Str #287 NSB, New Haven, CT 06520-8032, USA
    Crit Rev Oncol Hematol 49:119-33. 2004
    ..Novel molecular targeted therapies are among the strategies currently being investigated in SCLC...
  35. ncbi Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure
    Athanassios Argiris
    Division of Hematology Oncology, Northwestern University, The Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Oncologist 8:350-60. 2003
    ..The incorporation of induction chemotherapy may improve the results of treatment by targeting systemic micrometastatic disease...
  36. ncbi Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go
    Jyoti D Patel
    Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    Crit Rev Oncol Hematol 50:175-86. 2004
    ..The goal of ongoing and future investigation is to identify which patients may benefit from this new therapeutic approach...
  37. ncbi Can current treatments for advanced non-small-cell lung cancer be improved?
    Athanassios Argiris
    JAMA 292:499-500. 2004
  38. ncbi Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, IL 60637, USA
    Clin Cancer Res 10:4922-32. 2004
    ..Refinements in radiotherapy, including intensity-modulated radiation therapy, may improve the tolerance for this regimen...
  39. ncbi Induction chemotherapy for resectable non-small-cell lung cancer
    Jyoti D Patel
    Department of Medicine, Feinberg School of Medicine, Northwestern University, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 18:1591-602; discussion 1602-3, 1606, 1611-2. 2004
    ..Randomized trials are under way to better define the role of induction therapy in the multimodality treatment of NSCLC...
  40. ncbi Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy
    Michael T Milano
    Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, 5841 S Maryland Ave, MC 9006, Chicago, IL 60637, USA
    Int J Radiat Oncol Biol Phys 61:1096-106. 2005
    ..5-Gy) radiotherapy delivered on alternating weeks (TFGX(2)) in locally advanced head-and-neck cancer. Here, we report the clinical outcome and late toxicity of TFGX(2) in a subset of patients previously irradiated to the head and neck...
  41. ncbi Pemetrexed: a novel antifolate agent enters clinical practice
    Victoria Kut
    Department of Medicine, Division of Hematology/Oncology, The Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA
    Expert Rev Anticancer Ther 4:511-22. 2004
    ..Future studies will better define and likely expand the role of pemetrexed for the treatment of cancer...
  42. ncbi Induction chemotherapy for head and neck cancer: will history repeat itself?
    Athanassios Argiris
    Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania 15232, USA
    J Natl Compr Canc Netw 3:393-403. 2005
    ..A number of randomized trials are planned or currently ongoing to investigate concurrent chemoradiotherapy with or without induction. These trials are anticipated to redefine the role of induction chemotherapy for head and neck cancer...
  43. ncbi Revisiting induction chemotherapy for head and neck cancer. References and reviews
    Athanassios Argiris
    Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA
    Oncology (Williston Park) 19:932-4, 939; discussion 939-45. 2005
    ..Platinum/taxane combinations are the preferred regimens for further study in the induction setting and a suitable platform with which to investigate the addition of novel targeted agents...
  44. ncbi Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer
    Athanassios Argiris
    Division of Hematology-Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
    Invest New Drugs 24:203-12. 2006
    ..Diarrhea was the most common toxicity. Antitumor activity was promising. The alteration of irinotecan pharmacokinetic parameters observed may not be clinically relevant...
  45. ncbi Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer
    Daniel J Haraf
    Department of Radiation and Cellular Oncology, University of Chicago, Chicago, Illinois 60637 1470, USA
    Clin Cancer Res 9:5936-43. 2003
    ..In an attempt to decrease toxicity without compromising local control, a second cohort of patients was treated with a lower dose of radiation to sites of potential microscopic disease...
  46. ncbi Epidemiology, staging, and screening of head and neck cancer
    Athanassios Argiris
    Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, USA
    Cancer Treat Res 114:15-60. 2003
  47. ncbi Swallowing dysfunction--preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: a critical review
    Bharat B Mittal
    Department of Radiology, Section of Radiation Oncology, Northwestern University Feinberg School of Medicine and Robert H. Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
    Int J Radiat Oncol Biol Phys 57:1219-30. 2003
  48. ncbi PET scan assessment of chemotherapy response in metastatic paraganglioma
    Athanassios Argiris
    Division of Hematology-Oncology, The Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA
    Am J Clin Oncol 26:563-6. 2003
    ..It is suggested that metabolic imaging with PET scans is superior to anatomical imaging with CT scans for the monitoring of patients with paragangliomas...
  49. ncbi Synergistic interactions between tamoxifen and trastuzumab (Herceptin)
    Athanassios Argiris
    Yale University School of Medicine, Department of Internal Medicine, New Haven, Connecticut 06510, USA
    Clin Cancer Res 10:1409-20. 2004
    ..In vitro, the individual drugs or combination produces a cytostatic effect. These results suggest that combined inhibition of ER and HER-2/neu signaling may represent a powerful approach to the treatment of breast cancer...
  50. ncbi Clinical applications of gene therapy in head and neck cancer
    Michalis V Karamouzis
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    Curr Gene Ther 7:446-57. 2007
    ..Systemic delivery of gene therapy may be also possible, albeit with several limitations. In this review we will discuss the rationale, delivery methods, and accumulated clinical data with cancer gene therapy in SCCHN...
  51. ncbi Update on the role of EGFR inhibitors in cancer therapeutics
    Michalis V Karamouzis
    Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    Cancer Treat Res 135:257-75. 2007
  52. ncbi Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)
    Victoria Kut
    Department of Medicine, Division of Hematology Oncology, Northwestern University, Chicago, IL, USA
    Am J Clin Oncol 30:45-50. 2007
    ..18F]Fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan is widely used for the staging evaluation of nonsmall cell lung cancer, however, its use in small cell lung cancer (SCLC) remains investigational...
  53. ncbi Malignant thymoma associated with fatal myocarditis and polymyositis in a 32-year-old woman with a history of hairy cell leukemia
    Adi Gidron
    Division of Hematology-Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
    Am J Clin Oncol 29:213-4. 2006